Autopsy report · NCT01562899
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
Cause of deathFunding or business
“Study was withdrawn due to scientific and business considerations.”
Life of this trial
- Registered 5 months before it started.
- Ran for about 2 years 7 months before it stopped.
- 77 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Pfizer
- Sponsor type
- Industry
- Conditions
- Metastatic Pancreatic Adenocarcinoma; BRAF Mutated Melanoma
- Interventions
- MEK162; AMG 479
- Participants
- 77
- Sites
- 9
- Countries
- Australia, Belgium, Canada, France, Italy, Spain, United Kingdom, United States
Trials that died the same way
- Safety and Efficacy Study for Corneal Collagen Cross-Linking in Eyes With Corneal Ectasia After Refractive Surgery
“This study was withdrawn for business reasons.” - Maxi-Analgesic Osteoarthritis (OA) Study
“The study was withdrawn for administrative reason” - Gabapentin and Oxcarbazepine for Chronic Neuropathic Pain in Children and Adolescents: A Clinical Effectiveness Study
“Study was withdrawn for feasibility-related concerns.” - Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults Who Are Hospitalized With Type A Influenza.
“Study is withdrawn due to company decision.” - Characteristic Analysis and Surgical Exploration for Acetabular Roof Fractures: Multicenter Retrospective Cohort Study
“Due to limited funding, the study is now being withdrawn.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.